GNAS-KO cells displayed increased sensitivity to BRAF ± EGFR inhibition, with CI scores showing synergy (Fig. 5h), indicating that treatment-dependent SFK activation in BRAFV600E CRC cells is downstream of PGE2–GNAS signaling. The gene discussed is GNAS; the disease is colorectal carcinoma.